- 07.03.2017
Vela Genomics Launches NGS Clinical Interpretation and Reporting
SINGAPORE – 7 MARCH, 2017 – Vela Genomics, a subsidiary of Vela Diagnostics, has launched TheraKey™ which aims to provide accurate Next-Generation Sequencing (NGS) clinical interpretation and reporting.
- 20.09.2016
Vela Genomics Launches Early Access to TheraKey™
SINGAPORE – 20 SEPTEMBER, 2016 – Vela Genomics, a subsidiary of Vela Diagnostics, announced today the availability of TheraKey™, a clinical interpretation reporting service, for early access customers.